Effect of Xinfang rhinitis capsules on efficacy and inflammatory cytokines in patients with chronic rhinosinusitis

Abstract

Objective To explore the effect of Xinfang rhinitis capsules on the efficacy and inflammatory cytokines in patients with chronic rhinosinusitis. Methods A total of 100 patients with CRS treated in our hospital from April 2017 to April 2019 were selected as the study subjects. They were divided into the observation group and the control group according to the random number table method. Patients in the control group were treated with roxithromycin capsules, while those in the observation group were treated with roxithromycin capsules combined with Xinfang rhinitis capsules to compare the clinical total effective rate, visual analog scale, Lund-Kennedy score, tumor necrosis factor-α, interleukin-6, and IL-8 levels, as well as the occurrence of adverse effects. Results Patients in the observation group had a significantly higher total clinical total effective rate compared with the control group; in both groups, patients had significantly lower VAS and Lund-Kennedy scores than before treatment, and had the lower levels of TNF, IL-6, and IL-8 after the treatment, and these levels in the observation group were remarkably reduced compared with the control group; no adverse effects occurred during treatment in either group. Conclusion The combined treatment of Roxithromycin capsules and Xinfang rhinitis capsules exhibited a good clinical efficacy in the treatment of CRS, which can relieve the clinical symptoms of patients, reduce the inflammatory response of patients without adverse reactions.